| |
Male (n = 167)
|
Female (n = 107)
|
All (n = 274)
|
|---|
|
Age (full range)
|
61 (24–88) years
|
60 (21–86) years
|
60 (21–88) years
|
|
Genotype
|
|
TTR mutation
|
105 (63%)
|
71 (66%)
|
176 (64%)
|
|
V30M
|
101 (96%)
|
70 (99%)
|
171 (97%)
|
|
Other
|
4 (4%)
|
1 (1%)
|
5 (3%)
|
|
No TTR mutation
|
26 (16%)
|
17 (16%)
|
43 (16%)
|
|
Not tested
|
36 (21%)
|
19 (18%)
|
55 (20%)
|
|
Symptom/findinga
|
|
Polyneuropathy
|
146 (87%)
|
100 (93%)
|
246 (90%)
|
|
Cardiomyopathy
|
62 (35%)
|
17 (16%)
|
79 (29%)
|
|
GI symptoms
|
43 (26%)
|
41 (38%)
|
84 (31%)
|
|
Eye complications
|
21 (13%)
|
26 (24%)
|
47 (17%)
|
|
Other symptoms
|
1 (0.5%)
|
2 (2%)
|
3 (1%)
|
|
Echocardiogram
|
|
IVSd ≥ 12 mm
|
68 (72%)
|
25 (45%)
|
93 (62%)
|
|
IVSd < 12 mm
|
26 (28%)
|
31 (55%)
|
57 (38%)
|
|
99mTc-DPD scint
|
|
Positive
|
18 (78%)
|
6 (46%)
|
24 (67%)
|
|
Negative
|
5 (22%)
|
7 (54%)
|
12 (33%)
|
|
Amyloid in first Bx
|
70 (42%)
|
39 (36%)
|
109 (40%)
|
- aEach individual can present with one or more symptom/finding; Bx: biopsy; GI: gastrointestinal; IVSd: interventricular septum diameter; scint: scintigraphy; TTR: transthyretin gene. Percentages are shown as column percentage within each heading/subheading
